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Abstract
Background: Streptococcus pneumoniae is an important cause of microbial disease in humans. The introduction of
multivalent vaccines has coincided with a dramatic decrease in the number of pneumococcal-related deaths. In
spite of this, at a global level, pneumococcal infection remains an important cause of death among children under
5 years of age and in adults 65 years of age or older. In order to properly manage patients and control the spread
of infection, a rapid and highly sensitive diagnostic method is needed for routine implementation, especially in
resource-limited regions where pneumococcal disease is most prevalent.
Methods: Using the gene encoding leader peptidase A as a molecular diagnostics target, a real-time RPA assay
was designed and optimised for the detection of S. pneumoniae in whole blood. The performance of the assay was
compared to real-time PCR in terms of its analytical limit of detection and specificity. The inhibitory effect of human
genomic DNA on amplification was investigated. The potential clinical utility of the assay was investigated using a
small number of clinical samples.
Results: The RPA assay has a limit of detection equivalent to PCR (4.0 and 5.1 genome equivalents per reaction,
respectively) and was capable of detecting the equivalent of <1 colony forming unit of S. pneumoniae when spiked
into human whole blood. The RPA assay was 100 % inclusive (38/38 laboratory reference strains and 19/19 invasive
clinical isolates) and 100 % exclusive; differentiating strains of S. pneumoniae species from other viridans group
streptococci, including S. pseudopneumoniae. When applied to the analysis of a small number (n = 11) of clinical
samples (blood culture positive for S. pneumoniae), the RPA assay was demonstrated to be both rapid and sensitive.
Conclusions: The RPA assay developed in this work is shown to be as sensitive and as specific as PCR. In terms
of reaction kinetics, the RPA assay is shown to exceed those of the PCR, with the RPA running to completion in
20 minutes and capable generating a positive signal in as little as 6 minutes. This work represents a potentially
suitable assay for application in point-of-care settings.
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Background
Streptococcus pneumoniae is a major cause of human
disease. It is estimated that more than 1.6 million
people, including more than 800,000 children under the
age of 5, die every year from pneumococcal infections
[1]. In addition to its role as a leading cause of
community-acquired pneumonia, S. pneumoniae is a
causative agent of a variety of other infections, including
otitis media, blood stream infection, spontaneous peri-
tonitis and meningitis [2]. Pneumococcal meningitis is a
form of pneumococcal disease associated with significant
mortality and morbidity in children. In developed coun-
tries, pneumococcal meningitis has a mortality rate of
17–30 % [3] and an associated risk of sequelae of 32 %
[4]. In developing countries, the mortality and morbidity
rates are much higher [5]. S. pneumoniae belongs to the
mitis subgroup of alpha-haemolytic (viridans) strepto-
cocci (VGS). Mitis group streptococci other than S.
pneumoniae are also associated with bacteraemia which
may be clinically non-significant but may also be associ-
ated with invasive disease, particularly in predisposed
patients such as the immunocompromised and those
with cardiac valve damage [6]. The mitis group organ-
isms, S. mitis, S. oralis and S. pseudopneumoniae, pos-
sess >99 % 16S rRNA sequence homology with S.
pneumoniae [7]. Furthermore, horizontal gene transfer
between streptococci can give rise to atypical strepto-
cocci that are difficult to classify using phenotypic
methods [8]. Given the close genotypic and phenotypic
relationship between mitis group streptococci, the differ-
entiation of pneumococcus from other VGS is challen-
ging [9].
Culture based methods are the gold standard for diag-
nosing invasive pneumococcal disease (IPD). However
culture based methods typically require at least several
hours to a day or more incubation before an organism is
detected. Furthermore, these methods often demonstrate
limited diagnostic sensitivity, particularly post antibiotic
treatment or in cases with low sample volume, as is
often the case with children [10, 11]. Molecular amplifica-
tion methods such as PCR and Loop-mediated isothermal
amplification (LAMP) have been used to diagnose IPD
[12, 13] . These methods are reported as sensitive, are not
reliant on having viable organisms and have the potential
to deliver more rapid results.
Recombinase polymerase amplification (RPA) is an
isothermal in vitro nucleic acid amplification technology
that uses a combination of recombinase protein, oligo-
nucleotide primers and a strand displacing polymerase
to amplify DNA sequences [14]. RPA is sensitive, rapid,
specific and robust (less sensitive to inhibitors than
PCR). RPA has been applied to the detection of a wide
variety of bacterial, viral and eukaryotic molecular tar-
gets [15–22]. The use of a fluorescent probe enables
monitoring of reactions in real-time and multiplexing
capabilities. Isothermal amplification strategies are of
great interest in molecular diagnostics, as they negate
the need for thermocycling, as is the case for PCR. The
isothermal nature of these techniques makes them
suitable for incorporation into devices capable of being
deployed at the point-of-care.
Molecular targets that have been used to identify S.
pneumoniae include a variety of genes, including the
Spn9802 fragment [23], the RecA gene [24] the 16S
rRNA gene [25], and virulence factor genes, such as
autolysin (lytA) [26] and pneumolysin (ply) [27, 28].
Whilst these targets have proven useful for the detection
of S. pneumoniae, their ability to unequivocally identify
S. pneumoniae remains problematic. For example, false
positives can occur with the lytA marker [29] and both
ply [30] and Spn9802 [23] are associated with false nega-
tive results. Leader peptidase A (LepA), also known as
Elongation Factor 4 (EF4), is one of the most conserved
bacterial proteins and is found in virtually all know ge-
nomes [31]. It functions as a ribosome dependant
GTPase, with the ability to back-translocate post-
translocational ribosomes and increase the active frac-
tion of newly translated proteins [32–34]. Its utility as a
diagnostic marker has been previously demonstrated in
a multiplex assay for the detection of the Mycobacterium
tuberculosis complex (MTC) [35, 36].
In this study, we have developed and performed a pre-
liminary evaluation of a real-time RPA assay based on
the LepA gene for the detection of S. pneumoniae. We
also developed a LepA based S. pneumoniae real-time
PCR assay to compare in terms of specificity and
sensitivity.
Methods
Bacterial strains and growth conditions
S. pneumoniae bacterial reference strains (n = 8), non-S.
pneumoniae reference strains (n = 54) and invasive S.
pneumoniae clinical isolates (n = 19) were evaluated in
this study (Table 1). All strains were cultured overnight
in brain heart infusion (BHI) medium (Oxoid, UK) at
37 °C. For enumeration, 100 μL of serially diluted bac-
terial suspensions were spread plated on Columbia blood
agar and incubated for 24 hrs.
DNA extraction
Following overnight culture, bacterial genomic DNA was
extracted and purified using the DNeasy Blood and
Tissue kit (Qiagen, Germany) according to the manufac-
turers’ instructions. Following purification, DNA was
quantified by fluorescence (Qubit DNA BR Assay, Life
technologies, UK). Genome equivalents (GE) were calcu-
lated based on an assumed genome size of 2.1 Mb [37].
For whole blood spiking experiments, from an overnight
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culture, the culture medium was 10-fold serially diluted
in BHI. 2 μL of the serially diluted bacterial suspensions,
were spiked into 98 μL of fresh human whole blood.
Subsequently, total genomic DNA was extracted and
purified using the DNeasy Blood and Tissue kit (Qiagen,
Germany) according to the manufacturers’ instructions,
with the exception that DNA was eluted in 20 μL H20
(rather than 200 μL buffer AE).
Primer and probe design
LepA sequences were obtained from GenBank (http://
www.ncbi.nlm.nih.gov/genbank), and the Functional Gene
Pipeline and Repository (FunGene; http://fungene.cme.
msu.edu) website. Sequences were aligned using the mul-
tiple sequence alignment tool ClustalW [38]. Following
alignment, S. pneumoniae specific PCR and RPA primers
and probes were manually designed (Table 2). The se-
quences were finally screened for homology using the
BLASTn algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
to confirm their specificity. All oligonucleotide primers and
probes were purchased from Integrated DNA Technologies
(Leuven, Belgium), with the exception of the RPA probe,
Table 1 Bacterial strains and reactivity in the RPA and PCR
assays
Organism Strain IDa RPA PCR
S. pneumoniae DSM 20566 + +
S. pneumoniae DSM 11865 + +
S. pneumoniae DSM 11866 + +
S. pneumoniae DSM 14377 + +
S. pneumoniae DSM 24048 + +
S. pneumoniae DSM 11868 + +
S. pneumoniae DSM 25971 + +
S. pneumoniae DSM 14378 + +
Clinical Isolates
S. pneumoniae Clinical Isolates (n = 19) + +
S. agalactiae Clinical isolate (n = 1) - -
N. meningitidis Clinical isolate (n = 1) - -
Non-S. pneumonia reference strains
S. agalactiae BCCM 15081 - -
S. agalactiae BCCM 15082 - -
S. agalactiae BCCM 15083 - -
S. agalactiae BCCM 15084 - -
S. agalactiae BCCM 15085 - -
S. agalactiae BCCM 15086 - -
S. agalactiae BCCM 15087 - -
S. agalactiae BCCM 15094 - -
S. agalactiae BCCM 15095 - -
S. anginosus BCCM 20563 - -
S. australis BCCM 15627 - -
S. bovis BCCM 20480 - -
S. canis BCCM 20715 - -
S. constellatus BCCM 20575 - -
S. cristatus DSM 8249 - -
S. downei DSM 5365 - -
S. dysgalactiae DSM 6176 - -
S. equi DSM 20561 - -
S. equinis DSM 20554 - -
S. gordonii DSM 6777 - -
S. infantis DSM 12492 - -
S. intermedius DSM 20573 - -
S. mitis DSM 12643 - -
S. mutans DSM 20523 - -
S. oralis DSM 20066 - -
S. parasanguinis DSM 6778 - -
S. perosis DSM 12493 - -
S. porcinus DSM 20725 - -
S. pseudopneumoniae DSM 18670 - -
S. pyogenes DSM 2072 - -
Table 1 Bacterial strains and reactivity in the RPA and PCR
assays (Continued)
S. pyogenes DSM 20565 - -
S. salivarius DSM 20560 - -
S. salivarius DSM 20617 - -
S. sanguinis DSM 20567 - -
S. sinensis DSM 14990 - -
S. suis DSM 9682 - -
S. uberis DSM 20569 - -
S. vestibularis DSM 5636 - -
H. influenzae DSM 4690 - -
H. influenzae DSM 11121 - -
H. parainfluenzae DSM 8978 - -
H. haemolyticus CCUG 15312 - -
H. somnus CCUG 12839 - -
N. meningitidis DSM 10036 - -
K. pneumoniae DSM 30184 - -
P. aeruginosa DSM 50071 - -
E. coli DSM 30083 - -
E. faecalis DSM 20317 - -
C. albicans CBS 2700 - -
B. fragilis DSM 2151 - -
M. cattarhalis DSM 11994 - -
S. aureus DSM 346 - -
aDSM Leibniz-Institut, DSMZ Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH, BCCM Belgian Coordinated Collections of Microorganisms,
CCUG Culture Collection, University of Göteborg, Sweden
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which was purchased from Biosearch Technologies
(Petaluma, California, USA).
Real-time recombinase polymerase amplification
RPA reactions were performed using the TwistAmp Exo®
kit (TwistDx, Cambridge, UK) and contained: 1 x rehy-
dration buffer, 4 μL forward and reverse primer (6 μM
each), 4 μL probe (6 μM) and 1 μL genomic DNA as the
amplification template. To initiate the reaction, 14 mM
magnesium acetate (2.5 μL at a concentration of
280 mM) was added. Reactions were performed in a
total volume of 50 μL at 40 °C in a portable real-time
fluorometer (Twista®, TwistDx) for 20 minutes with a
mixing and centrifugation step after the first 4 minutes.
External negative and positive amplification controls
were included in each run. The positive amplification
control consisted of 100 GE of the S. pneumoniae type
strain (DSM 20566) diluted in molecular grade water.
The no-template control (NTC) consisted of molecular
grade water.
Real-time PCR
All real-time PCR assays were performed using a Light-
Cycler® 480 real-time PCR instrument (Roche Diagnos-
tics, UK). PCR reactions were performed in 200 μL 12-
well optical strips (BIOplastics BV, The Netherlands) in
a total volume of 20 μL. Each reaction consisted of 1 x
LightCycler Probes Master mix (Roche Diagnostics, UK),
10pmoles each primer and 5pmoles of probe and 1 μL
genomic DNA as the amplification template. Negative
and positive amplification controls were included in each
run. The positive amplification control consisted of 100
GE of the S. pneumoniae type strain (DSM 20566) di-
luted in molecular grade water. The no template control
(NTC) consisted of molecular grade water. The cycling
parameters consisted of 1 cycle of 95 °C for 5mins
followed by 45 cycles of 95 °C for 10s, 60 °C for 15 s and
72 °C for 1 s.
Specificity analysis/determination
The specificity of both the RPA and PCR assays were
evaluated. Genomic DNA (5 × 104 GE) from a panel
of Streptococcus and non-Streptococcus organisms (see
Table 1) was tested in both RPA and PCR amplifica-
tion assays.
Sensitivity analysis/determination
The analytical limit of detection (95 % confidence level)
of the PCR and RPA assays were determined. S. pneumo-
niae (DSM 20566) genomic DNA was diluted in molecu-
lar grade water to 8, 7, 6, 5, 4, 3, 2, or 1 GE per
microliter. PCR and RPA reactions were then performed
using 1 μL of the diluted DNA as the amplification tem-
plate. Reactions were performed in replicates of twelve
and the subsequent data was analysed statistically (Pro-
bit, Minitab, Version 16).
Evaluation of inhibition of RPA by human DNA
In order to determine the limit of background human
DNA tolerated by the RPA and PCR reactions, varying
quantities of human genomic DNA (100, 200 and 400 ng)
were added to reactions containing 50, 20 or 4 S.
pneumoniae (DSM 20566) GE.
Blood spiking experiments
Human whole blood was collected from a healthy volun-
teer in EDTA vacutainers (Becton Dickinson and Com-
pany, Ireland). Two microliters of 10-fold serially diluted
bacterial suspensions (over five orders of magnitude)
were spiked into 98 μL of fresh (within 1 hr of sampling)
human whole blood. Aliquots (100 μL) of the serially di-
luted bacterial suspensions were plated on blood agar
for enumeration. The spiked blood samples were then
processed immediately to extract DNA. From the eluted
DNA (20 μL), 1 μL was then subjected to RPA or PCR
amplification.
Table 2 Nucleic Acid sequences of primers and probes











aThe nucleotide position refers to the LepA gene from S. pneumoniae strain SPNA45 (Genbank accession number NC_018594.1)
*indicates a phosphorothioate bond
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Clinical sample analysis using RPA and PCR
Whole blood was collected in EDTA blood tubes from
patients attending Galway University Hospital, suspected
of a bloodstream infection for routine full blood count
and from healthy volunteers. Generally, within 24 hours
of collection of patient blood, residual material was
collected, anonymised and then stored at −80 °C. Blood
collected from the healthy volunteers was also stored
at −80 °C. Subsequently, the samples were thawed on
ice and total genomic DNA was extracted from 100 μL
of sample and eluted in 20 μL molecular grade water
as described previously. For analysis, 1 μL or 5 μL of
the eluted genomic DNA was subjected to amplifica-
tion by RPA and PCR.
Ethical approval
Ethical approval for this study was granted by the
Ethics Committee of the Galway University Hospital,
Galway, Ireland. Participants were selected on the
basis of having blood cultures submitted to the De-
partment of Medical Microbiology for detection of
blood stream infection. Following full blood count,
patients for whom residual EDTA blood samples
were available were recruited into the study based
on the results of the blood culture (confirmed posi-
tive for the presence of S. pneumoniae). For controls,




The analytical specificities of both the RPA and real-time
PCR assays were determined and are shown in Table 1.
Both assays detected the 3 S. pneumoniae references
strains tested. Both assays also detected all invasive clinical
isolates (n = 19). Of the 39 other Streptococcus and non-
Streptococcus species that were tested, none were detected
by either of the assays, indicating the analytical specificity
of the assays (Table 1, Fig. 1).
Analytical limit of detection
Genomic DNA was serially diluted (100–1 GE per reac-
tion) in water and subjected to RPA. Initial experiments
suggested that the RPA was capable of detecting 1 GE
per reaction (Fig. 2). Subsequently, the analytical limit of
detection of both the RPA and real-time PCR assays
were measured by testing 12 replicates of serially diluted
genomic DNA from the S. pneumoniae type strain
(DSM 20566). The analytical limit of detection (95 %
confidence level) of the RPA and PCR assays was estab-
lished to be 4.1 and 5.1 GE per reaction, respectively.
Table 3 outlines the number of reactions producing a
positive result for each template quantity.
Assessment of inhibition and detection in whole blood
The degree to which the RPA reaction was inhibited by
the presence of human DNA was concentration depend-
ant, varying from no significant inhibition (100 ng; data
Fig. 1 RPA assay specificity. The graph shows the fluorescence intensity of an assay containing 100 genome equivalents (GE) of S. pneumoniae
(type strain; DSM20566), 5 x 104 GE of 6 streptococcus species and a no template control (NTC)
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not shown) to substantial inhibition in the presence of
400 ng human DNA (the highest tested). Whilst inhib-
ited, when spiked with 200 ng or 400 ng of human
DNA, 50, 20 and 4 S. pneumoniae GE were detected, all
producing signals above that of the negative control
reaction (Fig. 3). When the PCR reaction was spiked
with human DNA (100, 200 or 400 ng/reaction), there
was no discernible shift in threshold-cycle between
spiked and non-spiked reactions, indicating that the
PCR was not inhibited by the presence of human DNA
(data not shown).
The ability of the assays to detect S. pneumoniae
spiked into whole blood from a healthy volunteer was
also determined. Plate counts indicated that 0.0185,
0.185, 1.85, 18.5, 185 CFU had been spiked into 98 μL of
blood. Upon extraction, total DNA was eluted into
20 μL, of which 1 μL was subjected to RPA and PCR,
meaning that each reaction contained template genomic
DNA from 0.000925, 0.00925, 0.0925, 0.925 or 9.25 CFU
equivalents. Both the RPA and PCR assays detected
0.925 and 9.25 CFU equivalents per reaction (Fig. 4).
The lower quantities (0.000925, 0.00925, 0.0925 CFU)
were not detected.
Detection of S. pneumoniae in clinical samples
Eleven blood samples confirmed by culture to be posi-
tive for S. pneumoniae were subjected to analysis by
RPA and PCR. Both the RPA and PCR assays were posi-
tive for the same 8 of the 11 samples tested (Table 4).
For the remaining 3 S. pneumoniae positive samples,
5 μL of the purified DNA was subsequently tested in the
RPA and PCR assays, resulting in positive signals. Figure 5
shows representative RPA amplification curves from the
resultant DNA purified from 4 confirmed positive clinical
blood samples. RPA and PCR analysis of DNA extracted
from the blood of four healthy (culture negative) volun-
teers, produced negative results.
Discussion
Some 93 polysaccharide capsular types or serotypes of S.
pneumoniae have been identified [39]. The introduction
of a 7-, 13-, and more recently, a 23-valent conjugate
vaccine has been associated with a dramatic reduction in
Fig. 2 RPA assay sensitivity. The graph shows the fluorescence intensity obtained from the amplification of 100, 50, 25, 10 and 1 genome
equivalents of S. pneumoniae (type strain; DSM20566). A no template control (NTC) reaction is also shown
Table 3 Analytical sensitivity






Stress (GE) RPA PCR
8 12 12 12
7 12 12 12
6 12 12 12
5 12 12 11
4 12 12 11
3 12 9 8
2 12 8 9
1 12 8 4
The number of replicates producing positive signals following RPA and PCR
amplification of varying (8, 7, 6, 5, 4, 3, 2, or 1) S. pneumoniae genome
equivalents (GE)
Clancy et al. BMC Infectious Diseases  (2015) 15:481 Page 6 of 11
the number of deaths, particularly amongst children and
in adults (via a herd effect) due to pneumococcal infec-
tion [40, 41]. However, pneumococcal disease remains a
serious disease globally, particularly in children less than
two years old, the elderly (>65 years) and in immunocom-
promised individuals. Thus, a robust diagnostic assay cap-
able of the rapid, sensitive and specific detection of S.
pneumoniae in near-patient settings could play a significant
role in the reduction of pneumococcal disease related mor-
bidity and mortality, particularly in developing countries.
Isothermal in vitro nucleic acid amplification strat-
egies are of great interest in molecular diagnostics, as
they negate the need for thermocycling, as is the case
for PCR. In PCR, thermocycling is required to facilitate the
separation of double-stranded DNA to enable amplification.
The major isothermal amplification techniques currently
utilised include: Nucleic Acid Sequence based Amplifica-
tion (NASBA) [42], Transcription Mediated Amplification
(TMA) [43], Loop-Mediated Isothermal Amplifica-
tion (LAMP) [44], Helicase Dependant Amplification
(HDA) [45], Rolling Circle Amplification (RCA) [46]
and Strand Displacement Amplification (SDA) [47].
Of these, NASBA, TMA, RCA and SDA cannot be
considered truly isothermal as they require an initial
heating step to denature the target nucleic acid prior
to amplification. RPA, HDA and LAMP can be
considered truly isothermal, as there is no requirement for
a denaturation step to initiate amplification. The operating
temperature of LAMP is typically 60–65 °C, at which
temperature the nucleic acid target is in dynamic equilib-
rium, enabling the binding of primers to their target se-
quence and subsequent amplification. Whilst LAMP is
inexpensive to perform, primer design is complex and
multiplex amplification is at present difficult. Both HDA
and RPA use proteins to facilitate the binding of primers
to their respective template and both technologies enable
Fig. 3 RPA assay robustness. The graphs show the fluorescence intensity obtained from the amplification of 50, 20 and 4 genome equivalents
(GE) of S. pneumoniae (type strain; DSM20566), a in the absence of background human genomic DNA, b in the presence of 200 ng background
human genomic DNA and c in the presence of 400 ng background human genomic DNA. Also shown in each graph is the fluorescence
intensity obtained from the amplification of 100 GE (positive control, PC) of S. pneumoniae (type strain; DSM20566) and a no template control
reaction (NTC)
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multiplex amplification. The major advantage of RPA over
other competing isothermal amplification technologies is
its speed, being capable of amplifying single-digit copy
numbers of nucleic acids to detectable levels in 5–10
minutes.
In this study, we have developed real-time RPA and
real-time PCR assays for the detection of S. pneumoniae
using primers and probes targeting the LepA gene. We
examined the ability of both assays to detect S. pneumo-
niae spiked into human whole blood. Finally, we applied
both assays to the detection of S. pneumoniae directly in
the blood of 11 patients confirmed positive for infection
by blood culture.
Both RPA and PCR assays were highly specific, with
all laboratory strains (n = 8) and clinical isolates of S.
pneumoniae (n = 19) positively identified. Both assays
were negative for all non-S. pneumoniae organisms (n =
39) assayed. These data support the results of our in
silico analysis, demonstrating that the LepA gene has
sufficient sequence heterogeneity to enable the specific
detection of S. pneumoniae. Probit regression analysis
was used to calculate (with 95 % confidence) the analyt-
ical LOD of both assays. The RPA assay had a marginally
better LOD than the PCR assay (4.0 and 5.1 GE respect-
ively). Assuming Poisson distribution, both assays dem-
onstrated limits of detection approaching 3 molecules,
the most sensitive LOD theoretically possible [48]. It
should also be noted that the RPA reactions were per-
formed in volumes of 50 μL, 250 % greater than the
20 μL PCR reactions, suggesting that by reducing the
reaction volume and thereby increasing the effective
concentration of the initial template DNA, the assay
sensitivity could be further improved.
RPA is a rapid isothermal in vitro nucleic acid amplifi-
cation technology. When 10 S. pneumoniae GE were
Fig. 4 Blood spiking. The graph shows the fluorescence intensity obtained from the RPA of 1 μL purified DNA (9.25, 0.925 and 0.0925 CFU
equivalents) extracted from whole blood spiked with varying CFU of S. pneumoniae (type strain; DSM20566). Also shown is the fluorescence
intensity obtained from the amplification of 100 GE (positive control, PC) of S. pneumoniae (type strain; DSM20566) and a no template control
reaction (NTC)
Table 4 Analysis of clinical samples. RPA and PCR assay
reactivity
Sample IDa RPA / PCRb
1 μL 5 μL
BS 12/2013/1 +
BS 12/2013/2 +




EM 03/2012 - +








aSamples HC1, HC2, HC3 and HC4 were obtained from healthy individuals
b1 or 5 μL of purified DNA was required to produce a positive signal in the
RPA or PCR
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used as the template for amplification, our RPA assay
produced a positive signal in as little as 5 mins. This is
in contrast to 35 cycles (approximately 20mins), which
was required to produce a positive signal in our PCR
assay for the equivalent template quantity.
Prior to performing our spiking experiments we inves-
tigated what affect the presence of background human
DNA had on the RPA assay performance. We found that
in the presence of 400 ng background DNA (the highest
quantity tested), although considerably inhibited, the
RPA assay was capable of detecting 50, 20 and 4 GE, all
giving signals above the no template control reaction. In
the presence of 200 ng of background human DNA, the
RPA assay was also inhibited, but to a much lesser de-
gree than in the presence of 400 ng DNA. According to
the DNA extraction kit manufacturer (Qiagen), 3–6 μg
is the typical yield of genomic DNA obtained from
100 μL of mammalian blood. The DNA we used for the
inhibition studies was extracted using the DNeasy blood
and tissue kit and yields were in this range (data not
shown). Assuming the average yield is 4.5 μg DNA /100 μL
blood, and considering that we eluted our extracted DNA
into 20 μL, of which 1 μL is subjected to RPA, the quantity
of background human DNA in the RPA reaction is approxi-
mately 225 ng. We also tested the effect of background hu-
man DNA on the PCR assay and found that the reaction
was not inhibited, even in the presence of 400 ng of back-
ground DNA.
When spiked into whole blood, both PCR and RPA
assays were capable of detecting 0.925 CFU/reaction,
which equals 18.5 CFU equivalents/100 μL blood. Reac-
tions in the blood spiking experiment were performed in
duplicate and subsequently repeated to verify this result.
Peter et al. (2009) developed a real-time PCR assay tar-
geting the autolysin gene capable of detecting the
equivalent of 125 CFU in 1 mL whole blood [49]. It
should be noted, that CFU is an estimate of the number
of viable organisms present. CFU as a metric does not
account for the presence of dead, non-viable cells or for
organisms that tend to form clumps or grow as pairs or
chains and may well substantially underestimate the
number of living cells in a sample [50].
To further evaluate our RPA assay, we tested a small
number of S. pneumoniae culture positive (n = 11) and
culture negative (obtained from consenting volunteers)
blood samples (n = 4). All culture positive samples re-
sulted in positive signals when analysed by RPA and
PCR amplifications while the four culture negative sam-
ples were RPA and PCR negative. Eight of the 11 culture
positive samples produced positive signals for RPA and
PCR when tested with 1 μL of purified DNA. The
remaining three that tested negative using 1 μL of puri-
fied DNA, were then tested using 5 μL of purified DNA
in both assays, with both assays producing positive sig-
nals. This result hints at a reduced bacterial DNA load
or the presence of RPA and PCR reaction inhibitors in
the 3 of the 11 culture positive samples in question. This
may have been the result of lower bacterial cell load in
the samples, DNA degradation due to extended sample
processing time during sample acquisition.
Fig. 5 Analysis of clinical samples. The graph shows the fluorescence intensity from the amplification of extracted genomic DNA from 4 clinical
samples previously confirmed positive for S. pneumoniae by culture. Also shown in each chart is the fluorescence intensity obtained from the
amplification of 100 GE and a no template control reaction (NTC)
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Conclusions
We have developed a sensitive and specific real-time
RPA and a real-time PCR assay for the detection of S.
pneumoniae in clinical blood samples. We have shown
this assay to be as specific and as, sensitive as PCR when
applied to the detection of S. pneumoniae using the
LepA gene as a diagnostics target. This assay may find
utility as a rapid point-of-care diagnostic test for the de-
tection of S. pneumoniae. Future work will focus on the
development of an internal amplification control for the
assay and increasing the number of clinical samples to
fully validate the RPA assay.
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